Hepatic Resection for Hepatocellular Carcinoma: Do Contemporary Morbidity and Mortality Rates Demand a Transition to Ablation as First-Line Treatment?
Despite the rising incidence of hepatocellular carcinoma (HCC), challenges and controversy persist in optimizing treatment. As recent randomized trials suggest that ablation can have oncologic equivalence compared with resection for early HCC, the relative morbidity of the 2 approaches is a central...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Li, George Z. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2014transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
8 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Use of the graphite intercalation compound to produce low-defect graphene sheets for the photocatalytic enhancement of graphene/TiO - Tibodee, Ananya ELSEVIER, 2019, New York, NY |
|---|---|
| Übergeordnetes Werk: |
volume:218 ; year:2014 ; number:4 ; pages:827-834 ; extent:8 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.jamcollsurg.2013.12.036 |
|---|
| Katalog-ID: |
ELV017900794 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV017900794 | ||
| 003 | DE-627 | ||
| 005 | 20230625123017.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180602s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jamcollsurg.2013.12.036 |2 doi | |
| 028 | 5 | 2 | |a GBVA2014018000028.pica |
| 035 | |a (DE-627)ELV017900794 | ||
| 035 | |a (ELSEVIER)S1072-7515(14)00019-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 540 |a 530 |q VZ |
| 084 | |a ASIEN |q DE-1a |2 fid | ||
| 084 | |a 6,25 |2 ssgn | ||
| 084 | |a 35.90 |2 bkl | ||
| 084 | |a 33.61 |2 bkl | ||
| 084 | |a 51.00 |2 bkl | ||
| 100 | 1 | |a Li, George Z. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hepatic Resection for Hepatocellular Carcinoma: Do Contemporary Morbidity and Mortality Rates Demand a Transition to Ablation as First-Line Treatment? |
| 264 | 1 | |c 2014transfer abstract | |
| 300 | |a 8 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Despite the rising incidence of hepatocellular carcinoma (HCC), challenges and controversy persist in optimizing treatment. As recent randomized trials suggest that ablation can have oncologic equivalence compared with resection for early HCC, the relative morbidity of the 2 approaches is a central issue in treatment decisions. Although excellent contemporary perioperative outcomes have been reported by a few hepatobiliary units, it is not clear that they can be replicated in broader practice. Our objective was to help inform this treatment dilemma by defining perioperative outcomes in a broader set of patients as represented in NSQIP-participating institutions. | ||
| 520 | |a Despite the rising incidence of hepatocellular carcinoma (HCC), challenges and controversy persist in optimizing treatment. As recent randomized trials suggest that ablation can have oncologic equivalence compared with resection for early HCC, the relative morbidity of the 2 approaches is a central issue in treatment decisions. Although excellent contemporary perioperative outcomes have been reported by a few hepatobiliary units, it is not clear that they can be replicated in broader practice. Our objective was to help inform this treatment dilemma by defining perioperative outcomes in a broader set of patients as represented in NSQIP-participating institutions. | ||
| 650 | 7 | |a AOR |2 Elsevier | |
| 650 | 7 | |a MELD |2 Elsevier | |
| 650 | 7 | |a SSI |2 Elsevier | |
| 650 | 7 | |a HCC |2 Elsevier | |
| 700 | 1 | |a Speicher, Paul J. |4 oth | |
| 700 | 1 | |a Lidsky, Michael E. |4 oth | |
| 700 | 1 | |a Darrabie, Marcus D. |4 oth | |
| 700 | 1 | |a Scarborough, John E. |4 oth | |
| 700 | 1 | |a White, Rebekah R. |4 oth | |
| 700 | 1 | |a Turley, Ryan S. |4 oth | |
| 700 | 1 | |a Clary, Bryan M. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Tibodee, Ananya ELSEVIER |t Use of the graphite intercalation compound to produce low-defect graphene sheets for the photocatalytic enhancement of graphene/TiO |d 2019 |g New York, NY |w (DE-627)ELV002771659 |
| 773 | 1 | 8 | |g volume:218 |g year:2014 |g number:4 |g pages:827-834 |g extent:8 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jamcollsurg.2013.12.036 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a FID-ASIEN | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 35.90 |j Festkörperchemie |q VZ |
| 936 | b | k | |a 33.61 |j Festkörperphysik |q VZ |
| 936 | b | k | |a 51.00 |j Werkstoffkunde: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 218 |j 2014 |e 4 |h 827-834 |g 8 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
g z l gz gzl |
|---|---|
| matchkey_str |
ligeorgezspeicherpauljlidskymichaeledarr:2014----:eairscinohptcluacrioaootmoayobdtadotltrtseadtast |
| hierarchy_sort_str |
2014transfer abstract |
| bklnumber |
35.90 33.61 51.00 |
| publishDate |
2014 |
| allfields |
10.1016/j.jamcollsurg.2013.12.036 doi GBVA2014018000028.pica (DE-627)ELV017900794 (ELSEVIER)S1072-7515(14)00019-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 530 VZ ASIEN DE-1a fid 6,25 ssgn 35.90 bkl 33.61 bkl 51.00 bkl Li, George Z. verfasserin aut Hepatic Resection for Hepatocellular Carcinoma: Do Contemporary Morbidity and Mortality Rates Demand a Transition to Ablation as First-Line Treatment? 2014transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Despite the rising incidence of hepatocellular carcinoma (HCC), challenges and controversy persist in optimizing treatment. As recent randomized trials suggest that ablation can have oncologic equivalence compared with resection for early HCC, the relative morbidity of the 2 approaches is a central issue in treatment decisions. Although excellent contemporary perioperative outcomes have been reported by a few hepatobiliary units, it is not clear that they can be replicated in broader practice. Our objective was to help inform this treatment dilemma by defining perioperative outcomes in a broader set of patients as represented in NSQIP-participating institutions. Despite the rising incidence of hepatocellular carcinoma (HCC), challenges and controversy persist in optimizing treatment. As recent randomized trials suggest that ablation can have oncologic equivalence compared with resection for early HCC, the relative morbidity of the 2 approaches is a central issue in treatment decisions. Although excellent contemporary perioperative outcomes have been reported by a few hepatobiliary units, it is not clear that they can be replicated in broader practice. Our objective was to help inform this treatment dilemma by defining perioperative outcomes in a broader set of patients as represented in NSQIP-participating institutions. AOR Elsevier MELD Elsevier SSI Elsevier HCC Elsevier Speicher, Paul J. oth Lidsky, Michael E. oth Darrabie, Marcus D. oth Scarborough, John E. oth White, Rebekah R. oth Turley, Ryan S. oth Clary, Bryan M. oth Enthalten in Elsevier Tibodee, Ananya ELSEVIER Use of the graphite intercalation compound to produce low-defect graphene sheets for the photocatalytic enhancement of graphene/TiO 2019 New York, NY (DE-627)ELV002771659 volume:218 year:2014 number:4 pages:827-834 extent:8 https://doi.org/10.1016/j.jamcollsurg.2013.12.036 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-ASIEN SSG-OLC-PHA 35.90 Festkörperchemie VZ 33.61 Festkörperphysik VZ 51.00 Werkstoffkunde: Allgemeines VZ AR 218 2014 4 827-834 8 045F 610 |
| spelling |
10.1016/j.jamcollsurg.2013.12.036 doi GBVA2014018000028.pica (DE-627)ELV017900794 (ELSEVIER)S1072-7515(14)00019-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 530 VZ ASIEN DE-1a fid 6,25 ssgn 35.90 bkl 33.61 bkl 51.00 bkl Li, George Z. verfasserin aut Hepatic Resection for Hepatocellular Carcinoma: Do Contemporary Morbidity and Mortality Rates Demand a Transition to Ablation as First-Line Treatment? 2014transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Despite the rising incidence of hepatocellular carcinoma (HCC), challenges and controversy persist in optimizing treatment. As recent randomized trials suggest that ablation can have oncologic equivalence compared with resection for early HCC, the relative morbidity of the 2 approaches is a central issue in treatment decisions. Although excellent contemporary perioperative outcomes have been reported by a few hepatobiliary units, it is not clear that they can be replicated in broader practice. Our objective was to help inform this treatment dilemma by defining perioperative outcomes in a broader set of patients as represented in NSQIP-participating institutions. Despite the rising incidence of hepatocellular carcinoma (HCC), challenges and controversy persist in optimizing treatment. As recent randomized trials suggest that ablation can have oncologic equivalence compared with resection for early HCC, the relative morbidity of the 2 approaches is a central issue in treatment decisions. Although excellent contemporary perioperative outcomes have been reported by a few hepatobiliary units, it is not clear that they can be replicated in broader practice. Our objective was to help inform this treatment dilemma by defining perioperative outcomes in a broader set of patients as represented in NSQIP-participating institutions. AOR Elsevier MELD Elsevier SSI Elsevier HCC Elsevier Speicher, Paul J. oth Lidsky, Michael E. oth Darrabie, Marcus D. oth Scarborough, John E. oth White, Rebekah R. oth Turley, Ryan S. oth Clary, Bryan M. oth Enthalten in Elsevier Tibodee, Ananya ELSEVIER Use of the graphite intercalation compound to produce low-defect graphene sheets for the photocatalytic enhancement of graphene/TiO 2019 New York, NY (DE-627)ELV002771659 volume:218 year:2014 number:4 pages:827-834 extent:8 https://doi.org/10.1016/j.jamcollsurg.2013.12.036 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-ASIEN SSG-OLC-PHA 35.90 Festkörperchemie VZ 33.61 Festkörperphysik VZ 51.00 Werkstoffkunde: Allgemeines VZ AR 218 2014 4 827-834 8 045F 610 |
| allfields_unstemmed |
10.1016/j.jamcollsurg.2013.12.036 doi GBVA2014018000028.pica (DE-627)ELV017900794 (ELSEVIER)S1072-7515(14)00019-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 530 VZ ASIEN DE-1a fid 6,25 ssgn 35.90 bkl 33.61 bkl 51.00 bkl Li, George Z. verfasserin aut Hepatic Resection for Hepatocellular Carcinoma: Do Contemporary Morbidity and Mortality Rates Demand a Transition to Ablation as First-Line Treatment? 2014transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Despite the rising incidence of hepatocellular carcinoma (HCC), challenges and controversy persist in optimizing treatment. As recent randomized trials suggest that ablation can have oncologic equivalence compared with resection for early HCC, the relative morbidity of the 2 approaches is a central issue in treatment decisions. Although excellent contemporary perioperative outcomes have been reported by a few hepatobiliary units, it is not clear that they can be replicated in broader practice. Our objective was to help inform this treatment dilemma by defining perioperative outcomes in a broader set of patients as represented in NSQIP-participating institutions. Despite the rising incidence of hepatocellular carcinoma (HCC), challenges and controversy persist in optimizing treatment. As recent randomized trials suggest that ablation can have oncologic equivalence compared with resection for early HCC, the relative morbidity of the 2 approaches is a central issue in treatment decisions. Although excellent contemporary perioperative outcomes have been reported by a few hepatobiliary units, it is not clear that they can be replicated in broader practice. Our objective was to help inform this treatment dilemma by defining perioperative outcomes in a broader set of patients as represented in NSQIP-participating institutions. AOR Elsevier MELD Elsevier SSI Elsevier HCC Elsevier Speicher, Paul J. oth Lidsky, Michael E. oth Darrabie, Marcus D. oth Scarborough, John E. oth White, Rebekah R. oth Turley, Ryan S. oth Clary, Bryan M. oth Enthalten in Elsevier Tibodee, Ananya ELSEVIER Use of the graphite intercalation compound to produce low-defect graphene sheets for the photocatalytic enhancement of graphene/TiO 2019 New York, NY (DE-627)ELV002771659 volume:218 year:2014 number:4 pages:827-834 extent:8 https://doi.org/10.1016/j.jamcollsurg.2013.12.036 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-ASIEN SSG-OLC-PHA 35.90 Festkörperchemie VZ 33.61 Festkörperphysik VZ 51.00 Werkstoffkunde: Allgemeines VZ AR 218 2014 4 827-834 8 045F 610 |
| allfieldsGer |
10.1016/j.jamcollsurg.2013.12.036 doi GBVA2014018000028.pica (DE-627)ELV017900794 (ELSEVIER)S1072-7515(14)00019-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 530 VZ ASIEN DE-1a fid 6,25 ssgn 35.90 bkl 33.61 bkl 51.00 bkl Li, George Z. verfasserin aut Hepatic Resection for Hepatocellular Carcinoma: Do Contemporary Morbidity and Mortality Rates Demand a Transition to Ablation as First-Line Treatment? 2014transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Despite the rising incidence of hepatocellular carcinoma (HCC), challenges and controversy persist in optimizing treatment. As recent randomized trials suggest that ablation can have oncologic equivalence compared with resection for early HCC, the relative morbidity of the 2 approaches is a central issue in treatment decisions. Although excellent contemporary perioperative outcomes have been reported by a few hepatobiliary units, it is not clear that they can be replicated in broader practice. Our objective was to help inform this treatment dilemma by defining perioperative outcomes in a broader set of patients as represented in NSQIP-participating institutions. Despite the rising incidence of hepatocellular carcinoma (HCC), challenges and controversy persist in optimizing treatment. As recent randomized trials suggest that ablation can have oncologic equivalence compared with resection for early HCC, the relative morbidity of the 2 approaches is a central issue in treatment decisions. Although excellent contemporary perioperative outcomes have been reported by a few hepatobiliary units, it is not clear that they can be replicated in broader practice. Our objective was to help inform this treatment dilemma by defining perioperative outcomes in a broader set of patients as represented in NSQIP-participating institutions. AOR Elsevier MELD Elsevier SSI Elsevier HCC Elsevier Speicher, Paul J. oth Lidsky, Michael E. oth Darrabie, Marcus D. oth Scarborough, John E. oth White, Rebekah R. oth Turley, Ryan S. oth Clary, Bryan M. oth Enthalten in Elsevier Tibodee, Ananya ELSEVIER Use of the graphite intercalation compound to produce low-defect graphene sheets for the photocatalytic enhancement of graphene/TiO 2019 New York, NY (DE-627)ELV002771659 volume:218 year:2014 number:4 pages:827-834 extent:8 https://doi.org/10.1016/j.jamcollsurg.2013.12.036 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-ASIEN SSG-OLC-PHA 35.90 Festkörperchemie VZ 33.61 Festkörperphysik VZ 51.00 Werkstoffkunde: Allgemeines VZ AR 218 2014 4 827-834 8 045F 610 |
| allfieldsSound |
10.1016/j.jamcollsurg.2013.12.036 doi GBVA2014018000028.pica (DE-627)ELV017900794 (ELSEVIER)S1072-7515(14)00019-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 530 VZ ASIEN DE-1a fid 6,25 ssgn 35.90 bkl 33.61 bkl 51.00 bkl Li, George Z. verfasserin aut Hepatic Resection for Hepatocellular Carcinoma: Do Contemporary Morbidity and Mortality Rates Demand a Transition to Ablation as First-Line Treatment? 2014transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Despite the rising incidence of hepatocellular carcinoma (HCC), challenges and controversy persist in optimizing treatment. As recent randomized trials suggest that ablation can have oncologic equivalence compared with resection for early HCC, the relative morbidity of the 2 approaches is a central issue in treatment decisions. Although excellent contemporary perioperative outcomes have been reported by a few hepatobiliary units, it is not clear that they can be replicated in broader practice. Our objective was to help inform this treatment dilemma by defining perioperative outcomes in a broader set of patients as represented in NSQIP-participating institutions. Despite the rising incidence of hepatocellular carcinoma (HCC), challenges and controversy persist in optimizing treatment. As recent randomized trials suggest that ablation can have oncologic equivalence compared with resection for early HCC, the relative morbidity of the 2 approaches is a central issue in treatment decisions. Although excellent contemporary perioperative outcomes have been reported by a few hepatobiliary units, it is not clear that they can be replicated in broader practice. Our objective was to help inform this treatment dilemma by defining perioperative outcomes in a broader set of patients as represented in NSQIP-participating institutions. AOR Elsevier MELD Elsevier SSI Elsevier HCC Elsevier Speicher, Paul J. oth Lidsky, Michael E. oth Darrabie, Marcus D. oth Scarborough, John E. oth White, Rebekah R. oth Turley, Ryan S. oth Clary, Bryan M. oth Enthalten in Elsevier Tibodee, Ananya ELSEVIER Use of the graphite intercalation compound to produce low-defect graphene sheets for the photocatalytic enhancement of graphene/TiO 2019 New York, NY (DE-627)ELV002771659 volume:218 year:2014 number:4 pages:827-834 extent:8 https://doi.org/10.1016/j.jamcollsurg.2013.12.036 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-ASIEN SSG-OLC-PHA 35.90 Festkörperchemie VZ 33.61 Festkörperphysik VZ 51.00 Werkstoffkunde: Allgemeines VZ AR 218 2014 4 827-834 8 045F 610 |
| language |
English |
| source |
Enthalten in Use of the graphite intercalation compound to produce low-defect graphene sheets for the photocatalytic enhancement of graphene/TiO New York, NY volume:218 year:2014 number:4 pages:827-834 extent:8 |
| sourceStr |
Enthalten in Use of the graphite intercalation compound to produce low-defect graphene sheets for the photocatalytic enhancement of graphene/TiO New York, NY volume:218 year:2014 number:4 pages:827-834 extent:8 |
| format_phy_str_mv |
Article |
| bklname |
Festkörperchemie Festkörperphysik Werkstoffkunde: Allgemeines |
| institution |
findex.gbv.de |
| topic_facet |
AOR MELD SSI HCC |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Use of the graphite intercalation compound to produce low-defect graphene sheets for the photocatalytic enhancement of graphene/TiO |
| authorswithroles_txt_mv |
Li, George Z. @@aut@@ Speicher, Paul J. @@oth@@ Lidsky, Michael E. @@oth@@ Darrabie, Marcus D. @@oth@@ Scarborough, John E. @@oth@@ White, Rebekah R. @@oth@@ Turley, Ryan S. @@oth@@ Clary, Bryan M. @@oth@@ |
| publishDateDaySort_date |
2014-01-01T00:00:00Z |
| hierarchy_top_id |
ELV002771659 |
| dewey-sort |
3610 |
| id |
ELV017900794 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV017900794</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625123017.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jamcollsurg.2013.12.036</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014018000028.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV017900794</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1072-7515(14)00019-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="a">530</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">ASIEN</subfield><subfield code="q">DE-1a</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">6,25</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.90</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">33.61</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Li, George Z.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Hepatic Resection for Hepatocellular Carcinoma: Do Contemporary Morbidity and Mortality Rates Demand a Transition to Ablation as First-Line Treatment?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Despite the rising incidence of hepatocellular carcinoma (HCC), challenges and controversy persist in optimizing treatment. As recent randomized trials suggest that ablation can have oncologic equivalence compared with resection for early HCC, the relative morbidity of the 2 approaches is a central issue in treatment decisions. Although excellent contemporary perioperative outcomes have been reported by a few hepatobiliary units, it is not clear that they can be replicated in broader practice. Our objective was to help inform this treatment dilemma by defining perioperative outcomes in a broader set of patients as represented in NSQIP-participating institutions.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Despite the rising incidence of hepatocellular carcinoma (HCC), challenges and controversy persist in optimizing treatment. As recent randomized trials suggest that ablation can have oncologic equivalence compared with resection for early HCC, the relative morbidity of the 2 approaches is a central issue in treatment decisions. Although excellent contemporary perioperative outcomes have been reported by a few hepatobiliary units, it is not clear that they can be replicated in broader practice. Our objective was to help inform this treatment dilemma by defining perioperative outcomes in a broader set of patients as represented in NSQIP-participating institutions.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">AOR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MELD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SSI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HCC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Speicher, Paul J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lidsky, Michael E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Darrabie, Marcus D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Scarborough, John E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">White, Rebekah R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Turley, Ryan S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Clary, Bryan M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Tibodee, Ananya ELSEVIER</subfield><subfield code="t">Use of the graphite intercalation compound to produce low-defect graphene sheets for the photocatalytic enhancement of graphene/TiO</subfield><subfield code="d">2019</subfield><subfield code="g">New York, NY</subfield><subfield code="w">(DE-627)ELV002771659</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:218</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:827-834</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jamcollsurg.2013.12.036</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-ASIEN</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.90</subfield><subfield code="j">Festkörperchemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">33.61</subfield><subfield code="j">Festkörperphysik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.00</subfield><subfield code="j">Werkstoffkunde: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">218</subfield><subfield code="j">2014</subfield><subfield code="e">4</subfield><subfield code="h">827-834</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Li, George Z. |
| spellingShingle |
Li, George Z. ddc 610 ddc 540 fid ASIEN ssgn 6,25 bkl 35.90 bkl 33.61 bkl 51.00 Elsevier AOR Elsevier MELD Elsevier SSI Elsevier HCC Hepatic Resection for Hepatocellular Carcinoma: Do Contemporary Morbidity and Mortality Rates Demand a Transition to Ablation as First-Line Treatment? |
| authorStr |
Li, George Z. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV002771659 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 540 - Chemistry & allied sciences 530 - Physics |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 540 530 VZ ASIEN DE-1a fid 6,25 ssgn 35.90 bkl 33.61 bkl 51.00 bkl Hepatic Resection for Hepatocellular Carcinoma: Do Contemporary Morbidity and Mortality Rates Demand a Transition to Ablation as First-Line Treatment? AOR Elsevier MELD Elsevier SSI Elsevier HCC Elsevier |
| topic |
ddc 610 ddc 540 fid ASIEN ssgn 6,25 bkl 35.90 bkl 33.61 bkl 51.00 Elsevier AOR Elsevier MELD Elsevier SSI Elsevier HCC |
| topic_unstemmed |
ddc 610 ddc 540 fid ASIEN ssgn 6,25 bkl 35.90 bkl 33.61 bkl 51.00 Elsevier AOR Elsevier MELD Elsevier SSI Elsevier HCC |
| topic_browse |
ddc 610 ddc 540 fid ASIEN ssgn 6,25 bkl 35.90 bkl 33.61 bkl 51.00 Elsevier AOR Elsevier MELD Elsevier SSI Elsevier HCC |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
p j s pj pjs m e l me mel m d d md mdd j e s je jes r r w rr rrw r s t rs rst b m c bm bmc |
| hierarchy_parent_title |
Use of the graphite intercalation compound to produce low-defect graphene sheets for the photocatalytic enhancement of graphene/TiO |
| hierarchy_parent_id |
ELV002771659 |
| dewey-tens |
610 - Medicine & health 540 - Chemistry 530 - Physics |
| hierarchy_top_title |
Use of the graphite intercalation compound to produce low-defect graphene sheets for the photocatalytic enhancement of graphene/TiO |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV002771659 |
| title |
Hepatic Resection for Hepatocellular Carcinoma: Do Contemporary Morbidity and Mortality Rates Demand a Transition to Ablation as First-Line Treatment? |
| ctrlnum |
(DE-627)ELV017900794 (ELSEVIER)S1072-7515(14)00019-2 |
| title_full |
Hepatic Resection for Hepatocellular Carcinoma: Do Contemporary Morbidity and Mortality Rates Demand a Transition to Ablation as First-Line Treatment? |
| author_sort |
Li, George Z. |
| journal |
Use of the graphite intercalation compound to produce low-defect graphene sheets for the photocatalytic enhancement of graphene/TiO |
| journalStr |
Use of the graphite intercalation compound to produce low-defect graphene sheets for the photocatalytic enhancement of graphene/TiO |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2014 |
| contenttype_str_mv |
zzz |
| container_start_page |
827 |
| author_browse |
Li, George Z. |
| container_volume |
218 |
| physical |
8 |
| class |
610 610 DE-600 540 530 VZ ASIEN DE-1a fid 6,25 ssgn 35.90 bkl 33.61 bkl 51.00 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Li, George Z. |
| doi_str_mv |
10.1016/j.jamcollsurg.2013.12.036 |
| dewey-full |
610 540 530 |
| title_sort |
hepatic resection for hepatocellular carcinoma: do contemporary morbidity and mortality rates demand a transition to ablation as first-line treatment? |
| title_auth |
Hepatic Resection for Hepatocellular Carcinoma: Do Contemporary Morbidity and Mortality Rates Demand a Transition to Ablation as First-Line Treatment? |
| abstract |
Despite the rising incidence of hepatocellular carcinoma (HCC), challenges and controversy persist in optimizing treatment. As recent randomized trials suggest that ablation can have oncologic equivalence compared with resection for early HCC, the relative morbidity of the 2 approaches is a central issue in treatment decisions. Although excellent contemporary perioperative outcomes have been reported by a few hepatobiliary units, it is not clear that they can be replicated in broader practice. Our objective was to help inform this treatment dilemma by defining perioperative outcomes in a broader set of patients as represented in NSQIP-participating institutions. |
| abstractGer |
Despite the rising incidence of hepatocellular carcinoma (HCC), challenges and controversy persist in optimizing treatment. As recent randomized trials suggest that ablation can have oncologic equivalence compared with resection for early HCC, the relative morbidity of the 2 approaches is a central issue in treatment decisions. Although excellent contemporary perioperative outcomes have been reported by a few hepatobiliary units, it is not clear that they can be replicated in broader practice. Our objective was to help inform this treatment dilemma by defining perioperative outcomes in a broader set of patients as represented in NSQIP-participating institutions. |
| abstract_unstemmed |
Despite the rising incidence of hepatocellular carcinoma (HCC), challenges and controversy persist in optimizing treatment. As recent randomized trials suggest that ablation can have oncologic equivalence compared with resection for early HCC, the relative morbidity of the 2 approaches is a central issue in treatment decisions. Although excellent contemporary perioperative outcomes have been reported by a few hepatobiliary units, it is not clear that they can be replicated in broader practice. Our objective was to help inform this treatment dilemma by defining perioperative outcomes in a broader set of patients as represented in NSQIP-participating institutions. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-ASIEN SSG-OLC-PHA |
| container_issue |
4 |
| title_short |
Hepatic Resection for Hepatocellular Carcinoma: Do Contemporary Morbidity and Mortality Rates Demand a Transition to Ablation as First-Line Treatment? |
| url |
https://doi.org/10.1016/j.jamcollsurg.2013.12.036 |
| remote_bool |
true |
| author2 |
Speicher, Paul J. Lidsky, Michael E. Darrabie, Marcus D. Scarborough, John E. White, Rebekah R. Turley, Ryan S. Clary, Bryan M. |
| author2Str |
Speicher, Paul J. Lidsky, Michael E. Darrabie, Marcus D. Scarborough, John E. White, Rebekah R. Turley, Ryan S. Clary, Bryan M. |
| ppnlink |
ELV002771659 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.jamcollsurg.2013.12.036 |
| up_date |
2024-07-06T17:28:24.279Z |
| _version_ |
1803851560943353856 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV017900794</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625123017.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jamcollsurg.2013.12.036</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014018000028.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV017900794</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1072-7515(14)00019-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="a">530</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">ASIEN</subfield><subfield code="q">DE-1a</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">6,25</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.90</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">33.61</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Li, George Z.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Hepatic Resection for Hepatocellular Carcinoma: Do Contemporary Morbidity and Mortality Rates Demand a Transition to Ablation as First-Line Treatment?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Despite the rising incidence of hepatocellular carcinoma (HCC), challenges and controversy persist in optimizing treatment. As recent randomized trials suggest that ablation can have oncologic equivalence compared with resection for early HCC, the relative morbidity of the 2 approaches is a central issue in treatment decisions. Although excellent contemporary perioperative outcomes have been reported by a few hepatobiliary units, it is not clear that they can be replicated in broader practice. Our objective was to help inform this treatment dilemma by defining perioperative outcomes in a broader set of patients as represented in NSQIP-participating institutions.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Despite the rising incidence of hepatocellular carcinoma (HCC), challenges and controversy persist in optimizing treatment. As recent randomized trials suggest that ablation can have oncologic equivalence compared with resection for early HCC, the relative morbidity of the 2 approaches is a central issue in treatment decisions. Although excellent contemporary perioperative outcomes have been reported by a few hepatobiliary units, it is not clear that they can be replicated in broader practice. Our objective was to help inform this treatment dilemma by defining perioperative outcomes in a broader set of patients as represented in NSQIP-participating institutions.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">AOR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MELD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SSI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HCC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Speicher, Paul J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lidsky, Michael E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Darrabie, Marcus D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Scarborough, John E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">White, Rebekah R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Turley, Ryan S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Clary, Bryan M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Tibodee, Ananya ELSEVIER</subfield><subfield code="t">Use of the graphite intercalation compound to produce low-defect graphene sheets for the photocatalytic enhancement of graphene/TiO</subfield><subfield code="d">2019</subfield><subfield code="g">New York, NY</subfield><subfield code="w">(DE-627)ELV002771659</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:218</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:827-834</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jamcollsurg.2013.12.036</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-ASIEN</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.90</subfield><subfield code="j">Festkörperchemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">33.61</subfield><subfield code="j">Festkörperphysik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.00</subfield><subfield code="j">Werkstoffkunde: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">218</subfield><subfield code="j">2014</subfield><subfield code="e">4</subfield><subfield code="h">827-834</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.399638 |